Tumor BRACAnalysis CDx
"Tumor BRACAnalysis CDx also has the potential to greatly expand the number of ovarian cancer patients who may respond to treatment with PARP inhibitors."
"In this study, tumor analysis identified substantially more patients with BRCA 1/2 mutations than germline blood testing alone," said Melinda Yates, Ph.D., of the MD Anderson Cancer Center in Houston, Texas and a study investigator. "The logical path forward is to use tumor testing to identify the greatest number of patients with BRCA 1/2 mutations."
Related links:
Developed by Web4Bio